electroCore, Inc. (ECOR)

electroCore's stock price has decreased by 73.71% over the last 12 months, but has seen a year-to-date return of 5.35%. Recent events include strong third-quarter financial results and preliminary guidance for full-year 2025, reimbursement approval in Belgium, participation in industry forums, advancements in product offerings, and a cash position of approximately $11.6 million at the end of 2025.

Seasonality trends suggest that January could be a particularly favorable month for electroCore based on historical data patterns.

electroCore, Inc. is a bioelectronic medicine and wellness company focused on non-invasive vagus nerve stimulation (nVNS) technology. Their products include gammaCore, a prescription nVNS therapy for pain and headache treatment; Quell neurostimulator, a prescription product for chronic pain; Truvaga, a direct-to-consumer wellness brand; and TAC-STIM, an nVNS product for military and government use.

electroCore has a presence in the United States, the United Kingdom, and other international markets. They have reimbursement approval in Belgium and plans for commercialization in Canada and the UK. Major customers include the U.S. Department of Veterans Affairs and the UK's National Health Service.

electroCore's brand reputation is generally positive due to product advancements and financial performance. The company is recognized for pioneering nVNS technology, and gammaCore is gaining traction as an effective treatment option. The company is committed to environmental responsibility by evolving gammaCore into a reusable medical device. Positive financial results and expected revenue growth further contribute to a favorable perception.

electroCore has 39 institutional owners and shareholders holding 788,551 shares. Major institutional owners include Vanguard Group Inc. and Renaissance Technologies Llc. Joseph P. Errico is the largest individual shareholder, owning 48.30% of the company. Individual insiders collectively own 30.6% of the company.